EUCTR2011-003694-29-IT进行中（未招募）不适用
A Phase 3b, Multi-Center, Open-label Study to Assess the Safety of Novartis Meningococcal B Recombinant Vaccine When Administered at a 0, 2-Month Schedule in Healthy at-risk Adults
OVARTIS VACCINES AND DIAGNOSTICS S.R.L.0 个研究点目标入组 130 人开始时间: 2012年2月20日最近更新:
适应症
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
- 发起方
- 入组人数
- 130
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •1. 18 – 60 years of age inclusive who have given written informed consent at the time of enrollment; 2. Able to comprehend and follow all required study procedures; 3. Who are available for all the visits scheduled in the study (i.e., not planning to leave the area before the end of the study period); 4. In good health as determined by the outcome of medical history, physical examination and clinical judgment of the investigator; 5. Who were or might be routinely exposed to N. meningitidis cultures and/or are travelling to geographical areas considered at high risk for epidemic Meningococcal B infection disease.
- •Are the trial subjects under 18? no
- •Number of subjects for this age range: 0
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 130
- •F.1.3 Elderly (>=65 years) no
- •F.1.3.1 Number of subjects for this age range
排除标准
- •1.Significant acute or chronic infection within the previous 7 days or fever (defined as axillary temperature = 38°C|100.4ºF) within the previous day; 2.Antibiotics within 3 days (72 hours) prior to enrollment; 3. Pregnancy or nursing (breastfeeding) mothers; 4. Females who have not used or do not plan to use acceptable birth control measures, for the 3 months duration of the study. Oral, injected or implanted hormonal contraceptive, diaphragm, condom, intrauterine device or sexual abstinence are considered acceptable forms of birth control. If sexually active the subject must have been using one of the accepted birth control methods for at least 30 days prior to study entry; 5.Any serious chronic or progressive disease (e.g., neoplasm, diabetes, cardiac disease, hepatic disease, progressive neurological disease or seizure disorder; autoimmune disease, HIV infection or AIDS, or blood dyscrasias or diathesis, signs of cardiac or renal failure or severe malnutrition); 6.Known or suspected impairment/alteration of the immune system, immunosuppressive therapy, including use of corticosteroids in immunosuppressive doses or chronic use of inhaled high-potency corticosteroids within the previous 60 days. [Use of topical corticosteroids administered during the study in limited areas (i.e., eczema on knees or face or elbows) of the body is allowed]; immunostimulants; 7.History of severe allergic reactions after previous vaccinations or hypersensitivity to any vaccine component; 8.Any condition which in the opinion of the investigator may interfere with evaluation of the study objectives.
研究者
相似试验
进行中（未招募）
不适用
This clinical study investigates the effectiveness and safety of Biostate in children with von Willebrand’s disease (VWD), a blood clotting disorder. A two day investigation of the pharmacokinetics on 0,5, 4 8 12 24 and 48 h after administration (metabolism of Biostate by the child’s body) is a part of the investigation.Von Willebrand DiseaseMedDRA version: 14.1Level: PTClassification code 10047715Term: Von Willebrand's diseaseSystem Organ Class: 10010331 - Congenital, familial and genetic disordersEUCTR2009-017753-34-DECSL Behring GmbH12
进行中（未招募）
1 期
This clinical study investigates the effectiveness and safety of Biostate in children with von Willebrand's disease (VWD), a blood clotting disorder. A two day investigation of the pharmacokinetics (metabolism of Biostate by the child's body) is a part of the investigation – 0.5, 4, 8, 12, 24 and 48h after administration.Von Willebrand DiseaseMedDRA version: 14.0Level: PTClassification code 10047715Term: Von Willebrand's diseaseSystem Organ Class: 10010331 - Congenital, familial and genetic disordersEUCTR2009-017753-34-BGCSL Behring GmbH12
招募中
3 期
A Study of Macitentan in Japanese Pediatric Participants with Pulmonary Arterial HypertensioPulmonary Arterial HypertensionJPRN-jRCT2011210057akano Masayoshi6
进行中（未招募）
1 期
A Study of Macitentan in Japanese Pediatric Patients with Pulmonary Arterial HypertensioMedDRA version: 21.1Level: PTClassification code 10064911Term: Pulmonary arterial hypertensionSystem Organ Class: 10038738 - Respiratory, thoracic and mediastinal disordersPulmonary arterial hypertensionEUCTR2023-000984-30-Outside-EU/EEAJanssen Pharmaceutical K.K.
已完成
3 期
A Phase 3 Study to Assess the Safety and Efficacy of BMN 165 in Japanese Adults With PhenylketonuriaPhenylketonuriaJPRN-jRCT2080224573BioMarin Pharmaceutical Inc./CMIC Co., Ltd.10